+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Successful treatment of suspected essential thrombocythaemia in the dog

Journal of Small Animal Practice 31(7): 345-348

Successful treatment of suspected essential thrombocythaemia in the dog

Essential thrombocythaemia in an eight-year-old Irish Setter is described. The condition was characterized by an autonomous overproduction of thrombocytes in the absence of overt leukaemia. This is believed to be the first recorded case of this condition in the dog.

Accession: 001959696

DOI: 10.1111/j.1748-5827.1990.tb00827.x

Download PDF Full Text: Successful treatment of suspected essential thrombocythaemia in the dog

Related references

Williams, J.M.; Schlesinger, P.E.; Gray, A.G., 1994: Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon. A 27-year-old woman with essential thrombocythemia (ET) had three miscarriages. She was treated with alpha interferon which was continued after she became pregnant again. The platelet count remained well controlled and at term she delivered a heal...

Simpson J.W.; Else R.W.; Honeyman P., 1990: Successful treatment of suspected essential thrombocythemia in the dog. Journal of Small Animal Practice 31(7): 345-348

Jayasekara, W.M.N.D.; Abeyratne, S.A.S.P.; Kulathilake, C.; Gunawardena, D.; Wijesiriwardena, I.S., 2015: Successful management of a pregnancy complicated by essential thrombocythaemia with pegylated interferon. Ceylon Medical Journal 60(2): 72-73

Penka, M.; Schwarz, J.; Ovesná, P.; Hlusí, A.; Korístek, Z.; Doubek, M.; Dulícek, P.; Pospísilová, D.; Kissová, J.; Buliková, A.; Pavlík, T., 2010: Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010. In the Czech Republic, anagrelid is used according to the recommendations of the Czech Working Group on Myeloproliferative Disorders for treatment ofthrombocythaemias associated with chronic myeloproliferative disorders--mainly essential thrombocy...

Buyukbayrak, E.Esim.; Ergen, B.; Karageyim Karsidag, A.Yasemin.; Kars, B.; Turan, C.; Birtas Atesoglu, E., 2010: Successful pregnancy in a patient with portal hypertension secondary to portal vein thrombosis due to essential thrombocythaemia: a rare case. Essential thrombocythaemia (ET) is a disease characterized by an increased platelet count, megakaryocytic hyperplasia and a hemorrhagic or thrombotic tendency. Pregnancy in patients with ET can have a favorable outcome. However, ET has also been r...

Randi, M.Luigia.; Putti, M.Caterina., 2004: Essential thrombocythaemia in children: is a treatment needed?. The myeloproliferative disorder, essential thrombocythaemia (ET), is extremely rare in children. In adults, thrombosis is the most common complication whereas a low number of children develop thrombosis and/or haemorrhages. Diagnosis of ET is ofte...

Bellucci, S.; Harousseau, J.L.; Brice, P.; Tobelem, G., 1988: Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 2(8617): 960-961

Wagner, S.; Waxman, J.; Sikora, K., 1989: The treatment of essential thrombocythaemia with radioactive phosphorus. The major complications of essential thrombocythaemia include haemorrhage and thrombosis, events which are related to the level of the abnormal platelet count. We report here on the use of radioactive phosphorus (32P) in eight patients with essent...

May, D.; Wandl, U.B.; Niederle, N., 1989: Treatment of essential thrombocythaemia with interferon alpha-2b. Lancet 1(8629): 96-96

Boban, A.; Sertić, D.; Radman, I.; Zupancić-Salek, S.; Zadro, R.; Labar, B., 2008: Anagrelide for treatment of patients with essential thrombocythaemia. Anagrelide is an imidazokinazoline derivate that reduces platelet production by interfering with megakaryocyte proliferation and maturation. As a non-cytostatic drug it selectively affects megakaryocyte lineage and therefore anemia and leukocytope...